Breast cancer, BRCA-mutated

From - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Fernandes Hermina WEB160x200.jpg
Hermina Fernandes, MD
Bismarck, ND
1 regimens on this page
3 variants on this page

Note: this page has regimens which are specific to breast cancer that is BRCA-mutated. Please see the main breast cancer page for other chemotherapy regimens.



Metastatic disease, all lines of therapy

Olaparib monotherapy

back to top

Variant #1, 100 mg BID

Study Evidence
Tutt et al. 2010 Phase II


Continued until progression

Variant #2, 300 mg BID

Study Evidence Comparator Efficacy
Robson et al. 2017 (OlympiAD) Phase III (E) Capecitabine
Superior PFS

Patients had confirmed deleterious or suspected deleterious germline BRCA mutation. This is the FDA-approved dose.


Continued until progression

Variant #3, 400 mg BID

Study Evidence
Tutt et al. 2010 Phase II
Kaufman et al. 2014 Phase II

Patients in Kaufman et al. 2014 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.


Continued until progression


  1. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. link to original article PubMed
  2. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, BalmaƱa J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol PubMed
  3. OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed

Additional resources